hP3

General Information


DRACP ID  DRACP00128

Peptide Name   hP3

Sequence  TFRAFLSSRLQDLYSIVRRADRAAV

Sequence Length  25

UniProt ID  P39060 

PubChem CID  Not available

Origin  Human endostatin peptides

Type  Native peptide

Classification

  

Active ACP Cancer targeted peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
BxPC-3 Pancreatic ductal adenocarcinoma Carcinoma No inhibition at 7 mg/kg/d Matrigel Assay 672 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  α5β1 integrin, metalloproteinases

Affinity  Not available

Mechanism  Inhibition of endothelial cell proliferation, migration, and tube formation

Nature  Anticancer; Antiangiogenesis



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00128

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C129H211N41O36

Absent amino acids  CEGHKMNPW

Common amino acids  R

Mass  334061

Pl  11.91

Basic residues  5

Acidic residues  2

Hydrophobic residues  12

Net charge  3

Boman Index  -6953

Hydrophobicity  -1.2

Aliphatic Index  101.6

Half Life 
  Mammalian: 30 hour
  Yeast: >20 hour
  E.coli: >10 hour

Extinction Coefficient cystines  1490

Absorbance 280nm  62.08

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 15867360

Title  A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity

Doi 10.1158/0008-5472.CAN-04-1833

Year  2005

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.